公开(公告)号：US20180135057A1

公开(公告)日：2018-05-17

申请号：US15564288

申请日：2016-04-08

申请人： ALNYLAM PHARMACEUTICALS, INC.

发明人： Gregory Hinkle

IPC分类号： C12N15/113 ,  A61K31/7125 ,  A61K31/712 ,  A61K47/26 ,  A61P17/00 ,  A61P25/28

CPC分类号： C12N15/1136 ,  A61K31/712 ,  A61K31/7125 ,  A61K47/26 ,  A61P1/16 ,  A61P17/00 ,  A61P25/28 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/335 ,  C12N2310/351 ,  C12N2310/3521 ,  C12N2310/3533

摘要： The invention relates to antisense polynucleotide agents targeting the LECT2 gene, and methods of using such antisense polynucleotide agents to inhibit expression of LECT2 and to treat subjects having a LECT2-associated disease, e.g., amyloidosis.

公开(公告)号：US20180133237A1

公开(公告)日：2018-05-17

申请号：US15834387

申请日：2017-12-07

申请人： SyneuRx International (Taiwan) Corp.

发明人： Guochuan Emil Tsai ,  Ching-Cheng Wang ,  Tien-Lan Hsieh ,  Yi-Wen Mao

IPC分类号： A61K31/7024

CPC分类号： A61K31/7024 ,  A23L33/10 ,  A23L33/105 ,  A23L33/30 ,  A23V2002/00 ,  A61K31/00 ,  A61K36/185 ,  A61K36/22 ,  A61K36/48 ,  A61K36/49 ,  A61K36/82 ,  A61K36/87 ,  A61K38/26 ,  A61K45/06 ,  A61P1/16 ,  A61P5/50 ,  A61P9/00 ,  A61P11/00 ,  A61P11/06 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07H1/08 ,  C07H13/08 ,  A61K2300/00

摘要： Methods for preparing tannic acid-containing compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions), particularly those having enriched tannic acid populations with superior potency, purity and safety profile. Also provide herein are the tannic acid-containing compositions for use in inhibiting D-amino acid oxidase and/or for treating CNS disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.

公开(公告)号：US20180111989A1

公开(公告)日：2018-04-26

申请号：US15562602

申请日：2016-03-31

申请人： HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

发明人： Rifaat SAFADI

IPC分类号： C07K16/28 ,  A61P1/16 ,  A61K38/17

CPC分类号： C07K16/28 ,  A61K38/16 ,  A61K38/1709 ,  A61K38/177 ,  A61K2039/505 ,  A61P1/16 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/76 ,  C07K2319/30

摘要： Provided is a method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction. Also provided are compositions including the agent.

公开(公告)号：US20180087028A1

公开(公告)日：2018-03-29

申请号：US15661191

申请日：2017-07-27

申请人： UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY)

发明人： Jeong Beom KIM ,  Myung Rae PARK

IPC分类号： C12N5/071 ,  C12N15/86 ,  A61P1/16 ,  A61K35/407 ,  G01N33/50

CPC分类号： C12N5/067 ,  A61K35/407 ,  A61P1/16 ,  C12N5/0672 ,  C12N15/85 ,  C12N15/86 ,  C12N2501/237 ,  C12N2501/38 ,  C12N2501/60 ,  C12N2501/603 ,  C12N2503/02 ,  C12N2506/1307 ,  C12N2506/14 ,  C12N2510/00 ,  C12N2740/15043 ,  G01N33/5067 ,  G01N33/5073

摘要： The present invention relates to a composition for inducing direct conversion from a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell (iHSC), a hepatocyte, and a cholangiocyte, and a method of direct conversion of a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell, a hepatocyte, and a cholangiocyte.

公开(公告)号：US20180042917A1

公开(公告)日：2018-02-15

申请号：US15551310

申请日：2016-02-16

申请人： POSTECH ACADEMY-INDUSTRY FOUNDATION ,  NOVMETAPHARMA CO., LTD.

发明人： Kyong Tai KIM ,  Hoe Yune JUNG

IPC分类号： A61K31/4706

CPC分类号： A61K31/4706 ,  A61K31/47 ,  A61P1/16 ,  A61P3/00 ,  A61P3/04 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/12

摘要： The present invention relates to a novel use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof and specifically, to a metabolic disease prevention, alleviation or treatment use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof, the composition activating both peroxisome proliferator-activated receptor-gamma (PPAR-γ) and peroxisome proliferator-activated receptor-alpha (PPAR-α).

公开(公告)号：US20170281739A1

公开(公告)日：2017-10-05

申请号：US15507383

申请日：2015-09-21

申请人： HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

发明人： Yaron ILAN

IPC分类号： A61K38/57

CPC分类号： A61K38/57 ,  A61P1/16

摘要： Methods of treating liver diseases are provided. Accordingly there is provided a method of treating a liver disease selected from the group consisting of fatty liver disease and chronic liver rejection in a subject in need thereof, wherein said liver disease is not associated with genetic alpha-1 anti-trypsin (AAT) deficiency, the method comprising administering to the subject a therapeutically effective amount of AAT.

公开(公告)号：US20170105996A1

公开(公告)日：2017-04-20

申请号：US15294075

申请日：2016-10-14

申请人： Yaron ILAN ,  Doina Cosma ROMAN ,  Michael HAYDEN ,  Einat AMIT-ROMACH

发明人： Yaron ILAN ,  Doina Cosma ROMAN ,  Michael HAYDEN ,  Einat AMIT-ROMACH

IPC分类号： A61K31/52 ,  A61K9/00 ,  A61K9/20 ,  A61K45/06

CPC分类号： A61K31/52 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/2846 ,  A61K45/06 ,  A61P1/16 ,  A61K2300/00

摘要： Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering front type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.

公开(公告)号：US20170071968A1

公开(公告)日：2017-03-16

申请号：US15363303

申请日：2016-11-29

申请人： Alexander Vladimirovich DIKOVSKIY ,  Boris Anatolievich RUDOI ,  Oleg Valentinovich DOROZHKO

发明人： Alexander Vladimirovich DIKOVSKIY ,  Boris Anatolievich RUDOI ,  Oleg Valentinovich DOROZHKO

IPC分类号： A61K31/7032 ,  A61K31/702 ,  A61K31/575 ,  A61K36/28 ,  A61K31/683 ,  A61K31/357 ,  A61K9/00 ,  A61K31/7016 ,  A61K31/685

CPC分类号： A61K31/7032 ,  A23D7/005 ,  A23L33/10 ,  A23L33/21 ,  A23V2002/00 ,  A61K9/0053 ,  A61K31/357 ,  A61K31/52 ,  A61K31/575 ,  A61K31/66 ,  A61K31/683 ,  A61K31/685 ,  A61K31/7016 ,  A61K31/702 ,  A61K36/28 ,  A61K45/06 ,  A61P1/16 ,  A61K2300/00 ,  A23V2250/28 ,  A23V2200/3202 ,  A23V2200/32 ,  A23V2250/1842 ,  A23V2250/5046

摘要： The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses. The invention contributes to the liver's functional recovery in a short time and prevents disease recidivation owing to the recovery of cholesterol exchange and intestinal biocenosis as a result of the synergistic interaction of a hepatoprotector and a prebiotic, thereby also preventing hepatoprotector side effects.

摘要翻译： 本发明涉及药物，肝脏和药理学，可用于制备和使用基于肝保护剂和益生元的药物组合物，用于治疗和预防由脂质 - 胆固醇交换引起的肝脏疾病，并且选自以下组：胆汁淤积主要 胆固醇结石，酒精和非酒精性脂肪性肝炎，胆汁性肝硬化，胆固醇吸收胆囊和药物诱发和毒性肝损伤。 药物组合物通过口服给药，并含有作为活性剂的肝脏保护剂和益生元，其具有治疗有效剂量。 本发明在短时间内有助于肝脏的功能恢复，并且由于肝保护剂和益生元的协同相互作用，由于胆固醇交换和肠内生物死亡的恢复而防止疾病复发，从而也防止肝脏保护剂的副作用。

公开(公告)号：US20160317570A1

公开(公告)日：2016-11-03

申请号：US15206280

申请日：2016-07-10

申请人： Hadasit Medical Research Services and Development Ltd. ,  Ben-Gurion University of the Negev Research and Development Authority

发明人： Yaron ILAN ,  Gadi LALAZAR ,  Eyal SHTEYER ,  Ami BEN-YA'ACOV ,  Smadar COHEN ,  Tsiona ELKAYAM

IPC分类号： A61K31/738

CPC分类号： A61K31/738 ,  A61K31/734 ,  A61L27/20 ,  A61L31/042 ,  A61P1/16 ,  C08L5/04

摘要： The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.

摘要翻译： 本发明涉及在有需要的受试者中治疗肝脏疾病的方法。 更具体地，本发明的方法基于治疗有效量的至少一种生物相容性藻酸盐生物材料，其任何修饰以及它们的任何组合，优选全身施用。 本发明还提供了在患有肝脏障碍的受试者中维持血清白蛋白水平和/或降低血清AST和ALT的方法。 此外，本发明提供了使用本发明描述的藻酸盐生物材料减少患有肝脏疾病的受试者的损伤的肝组织中细胞凋亡和诱导细胞增殖的方法。

公开(公告)号：US20160145296A1

公开(公告)日：2016-05-26

申请号：US14952526

申请日：2015-11-25

申请人： Enanta Pharmaceuticals, Inc.

发明人： Yat Sun Or ,  Ruichao Shen ,  Peng Dai ,  Jiang Long ,  Xuechao Xing ,  Guoqiang Wang

IPC分类号： C07J43/00 ,  C07J31/00 ,  C07J9/00 ,  C07J41/00

CPC分类号： C07J43/003 ,  A61P1/16 ,  C07J9/00 ,  C07J9/005 ,  C07J17/00 ,  C07J31/006 ,  C07J41/0055 ,  C07J41/0061 ,  C07J41/0088 ,  C07J41/0094 ,  C07J51/00

摘要： The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.

摘要翻译： 本发明涉及式（IA）和式（IB）的化合物及其药学上可接受的盐，其中R1，R2，R3，R4，R5，R6，R7，R8，R9和m如本文所定义，药物组合物 包括这些化合物和这些化合物用于治疗TGR5介导的疾病或病症的方法。